Cited by

• Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.

  Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Fukuda T, et al. J Clin Pharmacol. 2011 Mar;51(3):309-20. doi: 10.1177/0091270010368542. Epub 2010 Apr 23. J Clin Pharmacol. 2011. PMID: 20418509 Free PMC article. Clinical Trial.
• Generics in transplantation medicine: Randomized comparison of innovator and substitution products containing mycophenolate mofetil
.

  Reigner B, Grange S, Bentley D, Banken L, Abt M, Hughes R, Scheubel E, Guentert TW. Reigner B, et al. Int J Clin Pharmacol Ther. 2019 Oct;57(10):506-519. doi: 10.5414/CP203487. Int J Clin Pharmacol Ther. 2019. PMID: 31397274 Free PMC article. Clinical Trial.
• Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

  Staatz CE, Tett SE. Staatz CE, et al. Clin Pharmacokinet. 2007;46(1):13-58. doi: 10.2165/00003088-200746010-00002. Clin Pharmacokinet. 2007. PMID: 17201457 Review.
• Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.

  Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H, Habuchi T, Suzuki T. Kagaya H, et al. Eur J Clin Pharmacol. 2007 Mar;63(3):279-88. doi: 10.1007/s00228-006-0248-2. Epub 2007 Jan 9. Eur J Clin Pharmacol. 2007. PMID: 17211619
• Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis.

  Joy MS, Hilliard T, Hu Y, Hogan SL, Wang J, Falk RJ, Smith PC. Joy MS, et al. Ann Pharmacother. 2009 Jun;43(6):1020-7. doi: 10.1345/aph.1L699. Epub 2009 Jun 2. Ann Pharmacother. 2009. PMID: 19491317 Free PMC article. Clinical Trial.